Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

X. Montalban, S. L. Hauser, L. Kappos, D. L. Arnold, A. Bar-Or, G. Comi, J. de Seze, G. Giovannoni, H. -P. Hartung, B. Hemmer, F. Lublin, K. W. Rammohan, K. Selmaj, A. Traboulsee, A. Sauter, D. Masterman, P. Fontoura, S. Belachew, H. Garren, N. MaironP. Chin, ORATORIO Clinical Investigators, Raymond Hupperts, J. S. Wolinsky

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)209-220
Number of pages12
JournalNew England Journal of Medicine
Volume376
Issue number3
DOIs
Publication statusPublished - 19 Jan 2017

Keywords

  • DOUBLE-BLIND
  • MULTICENTER TRIAL
  • CANCER-RISK
  • CD20
  • DEMYELINATION
  • PATHOLOGY
  • ANTIBODY
  • DAMAGE

Cite this